Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ultragenyx Pharmaceutical (RARE) Receivables (2016 - 2025)

Ultragenyx Pharmaceutical (RARE) has disclosed Receivables for 10 consecutive years, with $159.0 million as the latest value for Q4 2025.

  • Quarterly Receivables rose 82.76% to $159.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $159.0 million through Dec 2025, up 82.76% year-over-year, with the annual reading at $159.0 million for FY2025, 82.76% up from the prior year.
  • Receivables for Q4 2025 was $159.0 million at Ultragenyx Pharmaceutical, up from $114.6 million in the prior quarter.
  • The five-year high for Receivables was $159.0 million in Q4 2025, with the low at $2.9 million in Q2 2025.
  • Average Receivables over 5 years is $50.0 million, with a median of $38.2 million recorded in 2021.
  • The sharpest move saw Receivables skyrocketed 116.79% in 2022, then tumbled 97.32% in 2025.
  • Over 5 years, Receivables stood at $36.2 million in 2021, then fell by 6.35% to $33.9 million in 2022, then grew by 18.88% to $40.3 million in 2023, then soared by 115.88% to $87.0 million in 2024, then soared by 82.76% to $159.0 million in 2025.
  • According to Business Quant data, Receivables over the past three periods came in at $159.0 million, $114.6 million, and $2.9 million for Q4 2025, Q3 2025, and Q2 2025 respectively.